TY - JOUR
T1 - Population-Attributable Risk for Cardiovascular Disease Associated with Hypertension in Black Adults
AU - Clark, Donald
AU - Colantonio, Lisandro D.
AU - Min, Yuan I.
AU - Hall, Michael E.
AU - Zhao, Hong
AU - Mentz, Robert J.
AU - Shimbo, Daichi
AU - Ogedegbe, Gbenga
AU - Howard, George
AU - Levitan, Emily B.
AU - Jones, Daniel W.
AU - Correa, Adolfo
AU - Muntner, Paul
N1 - Funding Information:
Racial Differences in Stroke (REGARDS) study was supported by award number 5U54GM115428 from the National Institute of General Medical Sciences of the National Institutes of Health; grants R01HL117323, K24 HL125704, R01 HL080477, 1K01HL133468, K24 HL125704, and K24 HL111154 from the National Heart, Lung, and Blood Institute; and grants 15SFRN2390002 and 19CDA34760232 from the American Heart Association. The Jackson Heart Study (JHS) was supported and conducted in collaboration with Jackson State University (HHSN268201800013I), Tougaloo College (HHSN268201800014I), the Mississippi State Department of Health (HHSN26820180015I) and the University of Mississippi Medical Center (HHSN268201800010I, HHSN268201800011I, and HHSN268201800012I) contracts from the National Heart. Lung, and Blood Institute and the National Institute on Minority Health and Health Disparities.
Funding Information:
receiving other support from the National Heart, Lung, and Blood Institute during the conduct of the study. Dr Mentz reported receiving grants and personal fees from Amgen, AstraZeneca, Bayer, Merck, and Novartis during the conduct of the study; receiving research support from Akros, Amgen, AstraZeneca, Bayer, GlaxoSmithKline, Gilead, InnoLife, Luitpold/American Regent, Medtronic, Merck, Novartis, Otsuka, and ResMed; receiving grants from the National Institutes of Health; receiving honoraria from Abbott, Amgen Inc, AstraZeneca, Bayer AG, Boston Scientific Corporation, Janssen, Luitpold Pharmaceuticals Inc, Medtronic, Merck, Novartis, and ResMed; and serving on advisory boards for Amgen Inc, AstraZeneca, Boehringer Ingelheim, Luitpold Pharmaceuticals Inc, Merck, and Novartis. Dr Shimbo reported being a consultant for Abbott Vascular, Edward Lifesciences Corporation, Medtronic, and Tryton Medical Incorporated and conducting event ascertainment for trials (testing coronary and valvular disease interventions) outside the submitted work. Dr Levitan reported receiving grants and personal fees from Amgen and personal fees from Novartis outside the submitted work. Dr Muntner reported receiving grants from the National Institutes of Health and the American Heart Association during the conduct of the study and receiving grants from Amgen Inc outside the submitted work. No other disclosures were reported.
Funding Information:
The Reasons for Geographic and Racial Differences in Stroke (REGARDS) study was supported by award number 5U54GM115428 from the National Institute of General Medical Sciences of the National Institutes of Health; grants R01HL117323, K24 HL125704, R01 HL080477, 1K01HL133468, K24 HL125704, and K24 HL111154 from the National Heart, Lung, and Blood Institute; and grants 15SFRN2390002 and 19CDA34760232 from the American Heart Association. The Jackson Heart Study (JHS) was supported and conducted in collaboration with Jackson State University (HHSN268201800013I), Tougaloo College (HHSN268201800014I), the Mississippi State Department of Health (HHSN26820180015I) and the University of Mississippi Medical Center (HHSN268201800010I, HHSN268201800011I, and HHSN268201800012I) contracts from the National Heart. Lung, and Blood Institute and the National Institute on Minority Health and Health Disparities.
Publisher Copyright:
© 2019 American Medical Association. All rights reserved.
PY - 2019/12
Y1 - 2019/12
N2 - Importance: The prevalence of hypertension and the risk for hypertension-related cardiovascular disease (CVD) are high among black adults. The population-attributable risk (PAR) accounts for both prevalence and excess risk of disease associated with a risk factor. Objective: To examine the PAR for CVD associated with hypertension among black adults. Design, Setting, and Participants: This prospective cohort study used data on 12497 black participants older than 21 years without CVD at baseline who were enrolled in the Jackson Heart Study (JHS) from September 26, 2000, through March 31, 2004, and cardiovascular events were adjudicated through December 31, 2015. The Reasons for Geographic and Racial Differences in Stroke (REGARDS) study participants were enrolled from July 1, 2003, through September 12, 2007, and cardiovascular events were adjudicated through March 31, 2016. Data analysis was performed from March 26, 2018, through July 10, 2019. Exposures: Normal blood pressure and hypertension were defined using the 2017 American College of Cardiology/American Heart Association blood pressure guideline thresholds. Main Outcomes and Measures: The PAR for CVD associated with hypertension, calculated using multivariable-adjusted hazard ratios (HRs) for CVD, coronary heart disease, heart failure, and stroke associated with hypertension vs normal blood pressure. Prevalence of hypertension among non-Hispanic black US adults 21 years and older without CVD was calculated using data from the National Health and Nutrition Examination Survey, 2011-2014. Results: Of 12497 participants, 1935 had normal blood pressure (638 [33.0%] male; mean [SD] age, 53.5 [12.4] years), 929 had elevated blood pressure (382 [41.1%] male; mean [SD] age, 58.6 [11.8] years), and 9633 had hypertension (3492 [36.3%] male; mean [SD] age, 62.0 [10.3] years). For a maximum 14.3 years of follow-up, 1235 JHS and REGARDS study participants (9.9%) experienced a CVD event. The multivariable-adjusted HR associated with hypertension was 1.91 (95% CI, 1.48-2.46) for CVD, 2.41 (95% CI, 1.59-3.66) for coronary heart disease, 1.52 (95% CI, 1.01-2.30) for heart failure, and 2.20 (95% CI, 1.44-3.36) for stroke. The prevalence of hypertension was 53.2% among non-Hispanic black individuals. The PAR associated with hypertension was 32.5% (95% CI, 20.5%-43.6%) for CVD, 42.7% (95% CI, 24.0%-58.4%) for coronary heart disease, 21.6% (95% CI, 0.6%-40.8%) for heart failure, and 38.9% (95% CI, 19.4%-55.6%) for stroke. The PAR was higher among those younger than 60 years (54.6% [95% CI, 37.2%-68.7%]) compared with those 60 years or older (32.0% [95% CI, 11.9%-48.1%]). No differences were present in subgroup analyses. Conclusions and Relevance: These findings suggest that a substantial proportion of CVD cases among black individuals are associated with hypertension. Interventions to maintain normal blood pressure throughout the life course may reduce the incidence of CVD in this population.
AB - Importance: The prevalence of hypertension and the risk for hypertension-related cardiovascular disease (CVD) are high among black adults. The population-attributable risk (PAR) accounts for both prevalence and excess risk of disease associated with a risk factor. Objective: To examine the PAR for CVD associated with hypertension among black adults. Design, Setting, and Participants: This prospective cohort study used data on 12497 black participants older than 21 years without CVD at baseline who were enrolled in the Jackson Heart Study (JHS) from September 26, 2000, through March 31, 2004, and cardiovascular events were adjudicated through December 31, 2015. The Reasons for Geographic and Racial Differences in Stroke (REGARDS) study participants were enrolled from July 1, 2003, through September 12, 2007, and cardiovascular events were adjudicated through March 31, 2016. Data analysis was performed from March 26, 2018, through July 10, 2019. Exposures: Normal blood pressure and hypertension were defined using the 2017 American College of Cardiology/American Heart Association blood pressure guideline thresholds. Main Outcomes and Measures: The PAR for CVD associated with hypertension, calculated using multivariable-adjusted hazard ratios (HRs) for CVD, coronary heart disease, heart failure, and stroke associated with hypertension vs normal blood pressure. Prevalence of hypertension among non-Hispanic black US adults 21 years and older without CVD was calculated using data from the National Health and Nutrition Examination Survey, 2011-2014. Results: Of 12497 participants, 1935 had normal blood pressure (638 [33.0%] male; mean [SD] age, 53.5 [12.4] years), 929 had elevated blood pressure (382 [41.1%] male; mean [SD] age, 58.6 [11.8] years), and 9633 had hypertension (3492 [36.3%] male; mean [SD] age, 62.0 [10.3] years). For a maximum 14.3 years of follow-up, 1235 JHS and REGARDS study participants (9.9%) experienced a CVD event. The multivariable-adjusted HR associated with hypertension was 1.91 (95% CI, 1.48-2.46) for CVD, 2.41 (95% CI, 1.59-3.66) for coronary heart disease, 1.52 (95% CI, 1.01-2.30) for heart failure, and 2.20 (95% CI, 1.44-3.36) for stroke. The prevalence of hypertension was 53.2% among non-Hispanic black individuals. The PAR associated with hypertension was 32.5% (95% CI, 20.5%-43.6%) for CVD, 42.7% (95% CI, 24.0%-58.4%) for coronary heart disease, 21.6% (95% CI, 0.6%-40.8%) for heart failure, and 38.9% (95% CI, 19.4%-55.6%) for stroke. The PAR was higher among those younger than 60 years (54.6% [95% CI, 37.2%-68.7%]) compared with those 60 years or older (32.0% [95% CI, 11.9%-48.1%]). No differences were present in subgroup analyses. Conclusions and Relevance: These findings suggest that a substantial proportion of CVD cases among black individuals are associated with hypertension. Interventions to maintain normal blood pressure throughout the life course may reduce the incidence of CVD in this population.
UR - http://www.scopus.com/inward/record.url?scp=85074140753&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074140753&partnerID=8YFLogxK
U2 - 10.1001/jamacardio.2019.3773
DO - 10.1001/jamacardio.2019.3773
M3 - Article
C2 - 31642869
AN - SCOPUS:85074140753
SN - 2380-6583
VL - 4
SP - 1194
EP - 1202
JO - JAMA Cardiology
JF - JAMA Cardiology
IS - 12
ER -